We are live on ! Find out more
QTTB icon

Q32 Bio

92 hedge funds and large institutions have $37.8M invested in Q32 Bio in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 10

90% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 21

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

26% more funds holding

Funds holding: 7392 (+19)

14.75% more ownership

Funds ownership: 75.53%90.27% (+15%)

88% less call options, than puts

Call options by funds: $62K | Put options by funds: $498K

91% less capital invested

Capital invested by funds: $406M → $37.8M (-$368M)

Holders
92
Holders Change
+19
Holders Change %
+26.03%
% of All Funds
1.21%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
40
Increased
22
Reduced
10
Closed
21
Calls
$62K
Puts
$498K
Net Calls
-$436K
Net Calls Change
-$440K
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$7.75M
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
$7.2M
CG
3
Carlyle Group
District of Columbia
$3.78M
ACA
4
Acorn Capital Advisors
New York
$2.76M +$25.4M +803,425 New
SCM
5
Sio Capital Management
New York
$2.4M +$22M +697,413 New
MAM
6
Monaco Asset Management
Monaco
$1.98M +$18.2M +574,816 New
BlackRock
7
BlackRock
New York
$1.61M +$1.86M +58,783 +14%
AVM
8
Arch Venture Management
Illinois
$1.1M
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.09M +$984K +31,156 +11%
Temasek Holdings
10
Temasek Holdings
Singapore
$1.08M
P
11
Pfizer
New York
$956K +$8.77M +277,777 New
S
12
Sanofi
France
$840K +$7.71M +244,083 New
TOCUITCONY
13
Trustees of Columbia University in the City of New York
New York
$461K +$4.23M +133,903 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$459K +$47.2K +1,495 +1%
Mariner
15
Mariner
Kansas
$418K +$3.83M +121,427 New
State Street
16
State Street
Massachusetts
$397K +$170K +5,369 +5%
RhumbLine Advisers
17
RhumbLine Advisers
Massachusetts
$363K +$3.07M +97,196 +1,164%
ACH
18
ArrowMark Colorado Holdings
Colorado
$280K +$2.57M +81,482 New
Morgan Stanley
19
Morgan Stanley
New York
$251K +$1.78M +56,346 +341%
Northern Trust
20
Northern Trust
Illinois
$207K -$33.7K -1,068 -2%
N
21
Nuveen
North Carolina
$192K
Two Sigma Investments
22
Two Sigma Investments
New York
$183K +$1.68M +53,175 New
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
$173K +$1.59M +50,388 New
Fidelity Investments
24
Fidelity Investments
Massachusetts
$169K -$11.9M -377,122 -88%
UBS Group
25
UBS Group
Switzerland
$165K +$1.4M +44,340 +1,217%

QTTB Hedge Fund Activity: Q4 2024 in Review

92 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q4 2024, worth a combined $37.8M — down 91% from $406M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new QTTB positions and 21 closed out — a net gain of 19 holders — while 22 added to existing stakes and 10 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $22M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $18M sold.

  • 92 institutional investors held Q32 Bio (QTTB) as of Q4 2024, up from 73 in Q3 2024.
  • Funds reported $37.8M of Q32 Bio stock for Q4 2024, down 91% quarter-over-quarter.
  • 40 funds opened new Q32 Bio positions in Q4 2024 and 21 closed out, a net change of +19 holders.
  • The largest Q32 Bio buyer in Q4 2024 was Sio Capital Management, an estimated $22M added.
  • The largest Q32 Bio seller in Q4 2024 was Adage Capital Partners, an estimated $18M sold.

Based on aggregated 13F filings for Q4 2024.